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C O R R E S P O N D E N C E
Refractory myositis in a patient of Sjögren’s syndrome having 
only anti- SS- A (60 kDa) antibody
Dear Editor,
A 46- year- old Japanese female patient had noticed asymptom-
atic eruptions on her legs several years ago and visited our hospital 
in 2015. Physical examination showed purpuras with mild indura-
tion and scattered pigmentation (Figure 1A, B). Manual muscle 
test revealed muscle weakness with a score of 4 on her upper and 
lower extremities. Laboratory investigation showed an increase in 
serum creatine kinase (CK; 450 U/L), aldolase (9.0 IU/L), immuno-
globulin G (2315 mg/dL), and the presence of cryoglobulin, antinu-
clear antibody (×640; speckle pattern), and autoantibodies against 
SS- A/Ro (>1200 U/mL). Other autoantibodies were not detected 
by enzyme- linked immunosorbent assay. A biopsy specimen from 
a purpura on her leg showed leukocytoclastic vasculitis in the su-
perficial dermis (Figure 1C, D). Direct immunofluorescence exam-
ination demonstrated the deposition of C3 on the vessels in the 
superficial dermis. (Figure 1E). A deltoid muscle biopsy showed 
mild myositis (Figure 1F). A biopsy specimen from minor salivary 
gland on the lip showed more than 50 mononuclear cells infiltra-
tion (Figure 1G). Immunoprecipitation assays for RNA (left) using 
nonradiolabeled K562 cell extracts and for protein (right) using 35S- 
methionine- labeled K562 cell extracts in our case revealed anti- 
SS- A (60 kDa) antibody (Figure 1H). We diagnosed her with primary 
Sjögren's syndrome with myositis and hypergammaglobulinemic 
purpura. Regarding differential diagnosis, myopathy associated with 
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F I G U R E  1  (A and B) Clinical presentation at first visit. Physical examination showed a lot of purpura with mild induration and scattered 
pigmentation. (C and D) Histopathological findings of the cutaneous biopsy specimen from a purpura on her leg showed leukocytoclastic 
vasculitis in the superficial dermis [hematoxylin– eosin (H&E) staining; original magnification, ×40 (C) and ×400 (D)]. (E) Direct 
immunofluorescence examination demonstrated the deposition of C3 on the vessels in the superficial dermis. (F) A deltoid muscle biopsy 
showed mild myositis (H&E staining; original magnification, ×100). (G) A biopsy specimen for minor salivary gland on the lip showed more 
than 50 mononuclear cells infiltration around the gland (H&E staining; original magnification, ×200). (H) Immunoprecipitation assays for RNA 
(left) using nonradiolabeled K562 cell extracts and for protein (right) using 35S- methionine- labeled K562 cell extracts in our case revealed 
anti- SS- A (60 kDa) antibody




2  |    CORRESPONDENCE 
cryoglobulinemic vasculitis was included. While it is usually accom-
panied by arthralgia, peripheral neuropathy, and haematuria,1 she 
had no symptoms of them. To improve myositis, oral prednisolone 
of 20 mg/day was not enough and 45 mg (1 mg/kg) was needed. 
We reduced the dosage after 4 weeks; then, myositis recurred in 
2016. We additionally administered azathioprine (100 mg/day), in-
travenous immunoglobulin (IVIG; 400 mg/kg/day, 5 days, 3 times) 
in 2017, tacrolimus (2- 3 mg/day) in 2018, or methotrexate (4- 6 mg/
week) in 2019, which could not improve myositis completely.
Myositis in Sjögren's syndrome usually responds well to small or 
moderate doses of prednisolone without a recurrence.2 However, our 
case needed high doses of prednisolone and various additional treat-
ments for recurrences. Autoantibodies are divided into myositis- specific 
antibody (MSA) such as antimelanoma differentiation- associated gene 
5 (MDA5) and myositis- associated antibody (MAA) such as SS- B/La and 
SS- A/Ro. Whereas the concurrent presence of more than one MSA in 
one patient is rare, MAAs are frequently observed with MSAs. Two dif-
ferent targets of proteins, Ro52 and Ro60, were identified regarding SS- 
A. In general adult population having anti- SS- A antibodies, the profile of 
Ro52- Ro60+ was found in 24%.3 However, the profile of Ro52- Ro60+ 
seems to be extremely rare in Japanese patients with polymyositis/der-
matomyositis (PM/DM),4 and Sjögren's syndrome with myositis having 
only anti- SS- A antibody is also rare.2 Anti- SS- A antibody could induce 
PM/DM through activating interferon- α production.5 Recent studies 
reported that anti- SS- A/Ro52 antibody was a risk factor for relapse in 
PM/DM6 and associated with poor prognosis in anti- MDA5- antibody- 
positive PM/DM.7 Anti- SS- A/Ro60 antibody can function as a Y RNA- 
free protein,8 but the details are still unclear. These studies mentioned 
not about anti- SS- A/Ro60, but only about anti- SS- A/Ro52. We suggest 
a possibility that not only anti- SS- A/Ro52 but also anti- SS- A/Ro60 may 
contribute to the resistance in the same way.
KE Y WORDS




CONFLIC T OF INTERE S T
The authors declare no conflict of interest.
DECL AR ATION SEC TION
Approval of the research protocol: N/A.
Informed consent: Informed consent was obtained.
Registry and the Registration No. of the study/trial: N/A.
Animal Studies: N/A.
Hiraku Kokubu MD1
Yasuhito Hamaguchi MD, PhD2
Takeshi Kato MD, PhD1
Toshihiro Tanaka MD, PhD1
Noriki Fujimoto MD, PhD1
1Department of Dermatology, Shiga University of Medical 
Science, Otsu, Japan
2Department of Dermatology, Faculty of Medicine, Institute 
of Medical, Pharmaceutical and Health Sciences, Kanazawa 
University, Kanazawa, Japan
Correspondence
Hiraku Kokubu MD, Department of Dermatology, Shiga 




Hiraku Kokubu  https://orcid.org/0000-0003-4023-367X 
Yasuhito Hamaguchi  https://orcid.org/0000-0001-5305-7770 
Noriki Fujimoto  https://orcid.org/0000-0003-4051-0649 
R E FE R E N C E S
 1. Rodriguez- Perez N, Rodriguez- Navedo Y, Font YM, Vila LM. 
Inflammatory myopathy as the initial presentation of cryoglobuli-
naemic vasculitis. BMJ Case Rep. 2013;2013:bcr2013010117.
 2. Aoki A, Ono S, Ueda A, Hagiwara E, Tsuji T, Misumi M, et al. 
Myositis in primary Sjogren's syndrome: clinical and pathological 
report. Mod Rheumatol. 2003;13(1):57– 61.
 3. Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham B- 
N, et al. Diagnostic Utility of Separate Anti- Ro60 and Anti- Ro52/
TRIM21 Antibody Detection in Autoimmune Diseases. Front 
Immunol. 2019;10:444.
 4. Kubo M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K. 
Prevalence of 52- kd and 60- kd Ro/SS- A autoantibodies in Japanese 
patients with polymyositis/dermatomyositis. J Am Acad Dermatol. 
2002;47(1):148– 51.
 5. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm 
GV, Lundberg IE. A possible mechanism for endogenous activa-
tion of the type I interferon system in myositis patients with anti- 
Jo- 1 or anti- Ro 52/anti- Ro 60 autoantibodies. Arthritis Rheum. 
2007;56(9):3112– 24.
 6. Tatebe N, Sada K- E, Asano Y, Zeggar S, Hiramatsu S, Miyawaki Y, 
et al. Anti- SS- A/Ro antibody positivity as a risk factor for relapse 
in patients with polymyositis/dermatomyositis. Mod Rheumatol. 
2018;28(1):141– 6.
 7. Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, et al. 
Clinical significance of myositis- specific autoantibody profiles in 
Japanese patients with polymyositis/dermatomyositis. Medicine. 
2019;98(20):e15578.
 8. Boccitto M, Wolin SL. Ro60 and Y RNAs: structure, func-
tions, and roles in autoimmunity. Crit Rev Biochem Mol Biol. 
2019;54(2):133– 52.
How to cite this article: Kokubu H, Hamaguchi Y, Kato T, 
Tanaka T, Fujimoto N. Refractory myositis in a patient of 
Sjögren’s syndrome having only anti- SS- A (60 kDa) antibody. 
J Cutan Immunol Allergy. 2021;00:1– 2. https://doi.
org/10.1002/cia2.12218
